Cytokines and lymphoid populations as potential biomarkers in locally and borderline pancreatic adenocarcinoma

Date

2022

Authors

González Borja, Iranzu
Viúdez, Antonio
Alors-Pérez, Emilia
Ghanem, Ismael
Pazo-Cid, Roberto
Feliu, Jaime
Alonso, Laura
López López, Carlos

Director

Publisher

MDPI
Acceso abierto / Sarbide irekia
Artículo / Artikulua
Versión publicada / Argitaratu den bertsioa

Project identifier

  • AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/BFU2016–80360/
  • AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-105201RB-I00/ES/ recolecta
  • Gobierno de Navarra//008-2018/
Impacto
No disponible en Scopus

Abstract

Despite its relative low incidence, PDAC is one of the most aggressive and lethal types of cancer, being currently the seventh leading cause of cancer death worldwide, with a 5-year survival rate of 10.8%. Taking into consideration the necessity to improve the prognosis of these patients, this research has been focused on the discovery of new biomarkers. For this purpose, patients with BL and resectable disease were recruited. Serum cytokines and growth factors were monitored at different time points using protein arrays. Immune cell populations were determined by flow cytometry in peripheral blood as well as by immunohistochemistry (IHC) in tumor tissues. Several cytokines were found to be differentially expressed between the study subgroups. In the BL disease setting, two different scores were proven to be independent prognostic factors for progression-free survival (PFS) (based on IL-10, MDC, MIF, and eotaxin-3) and OS (based on eotaxin-3, NT-3, FGF-9, and IP10). In the same context, CA19-9 was found to play a role as independent prognostic factor for OS. Eotaxin-3 and MDC cytokines for PFS, and eotaxin-3, NT-3, and CKβ8-1 for OS, were shown to be predictive biomarkers for nab-paclitaxel and gemcitabine regimen. Similarly, oncostatin, BDNF, and IP10 cytokines were proven to act as predictive biomarkers regarding PFS, for FOLFIRINOX regimen. In the resectable cohort, RANTES, TIMP-1, FGF-4, and IL-10 individually differentiated patients according to their cancer-associated survival. Regarding immune cell populations, baseline high levels of circulating B lymphocytes were related to a significantly longer OS, while these levels significantly decreased as progression occurred. Similarly, baseline high levels of helper lymphocytes (CD4+), low levels of cytotoxic lymphocytes (CD8+), and a high CD4/CD8 ratio, were related to a significantly longer PFS. Finally, high levels of CD4+ and CD8+ intratumoural infiltration was associated with significantly longer PFS. In conclusion, in this study we were able to identify several prognostic and predictive biomarker candidates in patients diagnosed of resectable or BL PDAC.

Description

Keywords

B lymphocytes, Biomarkers, Borderline disease, Cytokines and growth factors, Flow cytometry and immunohistochemistry, Pancreatic ductal adenocarcinoma (PDAC), Protein arrays, Resectable disease, T lymphocytes

Department

Ciencias de la Salud / Osasun Zientziak

Faculty/School

Degree

Doctorate program

item.page.cita

González-Borja, I., Viúdez, A., Alors-Pérez, E., Goñ,i S., Amat, I., Ghanem, I., Pazo-Cid, R., Feliu, J., Alonso, L., López, C., Arrazubi, V., Gallego, J., Pérez-Sanz, J., Hernández-García, I., Vera, R., Castaño, J.P Fernández-Irigoyen, J. (2022) Cytokines and lymphoid populations as potential biomarkers in locally and borderline pancreatic adenocarcinoma. Cancers, 14(23), 1-18. https://doi.org/10.3390/cancers14235993.

item.page.rights

© 2022 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.

Licencia

Los documentos de Academica-e están protegidos por derechos de autor con todos los derechos reservados, a no ser que se indique lo contrario.